Drug news
BioMarin files Vimzim at EMA for Mucopolysaccharidosis Type IVA
BioMarin Pharmaceutical Inc. has announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome. A Biologics License Application for Vimizim was submitted to the FDA in March 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins